Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 1, 2006, Pages 45-51

  Quy, H T ^a   Cobelens, Frank G J ^b,c   Lan, N T N ^a   Buu, T N ^a   Lambregts, C S B ^b,d   Borgdorff, M W ^b,c  

^a Pham Ngoc Thach Hospital   (Viet Nam)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug resistance; HIV; Mortality; Treatment outcome; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DEATH; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM EXAMINATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; URBAN POPULATION; VIET NAM;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VIETNAM;

EID: 33144459579     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Frieden T R, Sterling T R, Munsiff S S, Watt C J, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
2. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
3. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
4. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152.
5. World Health Organization/International Union Against Tuberculosis and Lung Disease global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Report no. 2. Prevalence and trends. Geneva, Switzerland: WHO, 2000.
6. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
7. World Health Organization. Global Tuberculosis Control. WHO report 2001. WHO/CDS/TB/2001.287. Geneva, Switzerland: WHO, 2001.
8. Lindan C P, Lieu T X, Giang L T, et al. Rising HIV infection rates in Ho Chi Minh City herald emerging AIDS epidemic in Vietnam. AIDS 1997; 11 (Suppl 1): S5-S13.
9. Quy H T, Nhien D T, Lan N T, Borgdorff M W, Broekmans J F. Steep increase in HIV prevalence among tuberculosis patients in Ho Chi Minh City. AIDS 2002; 16: 931-932.
10. Quy H T, Lan N T, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
11. Espinal M A. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003; 7: 607-608.
12. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
13. International Union Against Tuberculosis and Lung Disease. The public health service national tuberculosis reference laboratory and the national laboratory network. Paris, France: IUATLD, 1998.
14. Hosmer D W, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons, 1989.
15. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.
16. Murray C, Styblo K, Rouillon A. Tuberculosis. In: Jamison D T, Mosley W H, Measham A R, Bobadilla J L, eds. Disease control priorities in developing countries. New York, NY: Oxford University Press, 1993.
17. Poprawski D, Pitisuttitum P, Tansuphasawadikul S. Clinical presentations and outcomes of TB among HIV-positive patients. Southeast Asian J Trop Med Public Health 2000; 31 (Suppl 1): 140-142.
18. Wiktor S Z, Sassan-Morokro M, Grant A D, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475.
19. Thornsberry C, Hill B C, Swenson J M, McDougal L K. Rifampin: spectrum of antibacterial activity. Rev Infect Dis 1983; 5 (Suppl 3): S412-S417.